Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin in COPD
NCT03989271Phase 2Unknown
- Sponsor
- Temple University
- Start
- Oct 2019
- Primary completion
- May 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Quercetin with Placebo (2 arms). Primary endpoints: Oxidative stress markers at 6 months and Inflammatory markers at 6 months. Status: unknown.
02
Drugs
quercetin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03989271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989271.